Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647011 | 1.00 | CA1 (0.63) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2654897 | 0.92 | CA1 (0.54) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16767423 | 0.89 | RAB9A (0.61) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7560695 | 0.86 | CA1 (0.47) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2647028 | 0.85 | HAO1 (0.52) | CA1CA2ALDH1A1MEN1KMT2A | |
| SCHEMBL7560701 | 0.85 | GCGR (0.48) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1790000 | 0.85 | ALDH1A1 (0.59) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2949436 | 0.85 | ALDH1A1 (0.59) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL2944396 | 0.85 | ALDH1A1 (0.59) | CA1CA2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL22453473 | 0.84 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2MAPTNPC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| EP-2854819-A2 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | The Governing Council of the University of Toronto (CA) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013177534-A2 | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2013-11-28 | — | — | WO | disclosed |
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | CA1 1168/4885CA2 865/4885ALDH1A1 722/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | CA1 1168/4885CA2 865/4885ALDH1A1 722/4885 |
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | CA1 4212/4885CA2 3563/4885ALDH1A1 4823/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | CA1 1168/4885CA2 865/4885ALDH1A1 722/4885 |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, JAK2 | CA1 732/4885CA2 505/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.